GLP‑1 real‑world data for obesity: A new standard for metabolic care
The rise of GLP-1 therapies and the evolution of obesity treatment Over 40% of adults in the U.S....
The rise of GLP-1 therapies and the evolution of obesity treatment Over 40% of adults in the U.S....
Turning claims into interoperable evidence More means more. In a world where anyone can make...
Digital health innovators and pharma leaders are under increasing pressure to show that new models...
(Part 2) In Part 1 we explored how HealthVerity Marketplace delivers high-quality,...
(Part 1) When clients see real-world data (RWD) in HealthVerity Marketplace, it may appear...
Electronic Health Records (EHR): What they are and how to use them in real-world data Electronic...
In this edition of our Ask an Expert series, we turn to Emery Niemiec, Senior Director,...
HealthVerity recently introduced HealthVerity Notes, our newest product designed to unlock the...
AI-driven mortality models are supposed to provide accurate, data-backed insights into patient...
The HealthVerity Marketplace webinar wrapped up with a clear message. The Marketplace model is not...
As the new year begins, many patients refocus on weight management and long-term health goals. At the same time, GLP-1 drugs have reshaped the obesity treatment landscape.1,2 With semaglutide and other GLP-1 medications in high demand for weight loss...